https://www.mayocliniclabs.com/

Contact Information:

Benjamin Levno
Levno.Benjamin@mayo.edu

James Cahoy
Cahoy.James@mayo.edu

Virtual Exhibit Hall Home

Mayo Clinic Laboratories offers a profile that can assist in the diagnosis of MS by measuring kappa light chains in cerebral spinal fluid (KCSF) with a reflex, if positive, to oligoclonal banding. Using our reflexive approach, answers for three-fourths of patients will be provided within the day that the test is run. Additional results for oligoclonal banding will be reported within three days.

We know the importance of distinguishing autoimmune demyelating diseases from MS. Identifying antibodies that are contributing factors in CNS demyelinating diseases allows physicians to provide a clear diagnosis for patients and implement an appropriate treatment regimen designed to reduce the risk of relapse. Due to significant overlap in the clinical phenotypes, we recommend testing AQP4 and MOG-IgGs at the same time and use this method in our neuromyelitis optica spectrum disorders testing. Mayo Clinic has developed the only fluorescence activated cell sorting (FACS) live cell-binding assay that is currently available in the U.S. for antibody detection of AQP4 and MOG. FACS is recommended by international leaders in neuroimmunology for its increased sensitivity and specificity.

Visit https://news.mayocliniclabs.com/neurology/ to view our full list of test offerings.

Neurology Requisition Form

Mayo Clinic Neurology Consultative Services

Autoimmune Neurology Antibody Matrix